radRounds Radiology Network

Connecting Radiology for Networking, Collaboration, and Education

(DIAGNOSTIC IMAGING, Greg Freiherr) -- Fluorine-18 unlocks door to Alzheimer’s diagnosis

An intractable foe of what makes people what they are suddenly seems vulnerable, and it is imaging that has struck the blow. In a clinical trial at Johns Hopkins University, a PET agent built around fluorine-18 readily and safely distinguished the brains of Alzheimer’s disease patients from those of healthy volunteers. And the Johns Hopkins researchers are not alone. Several pharma companies, big and small, are on the same track.

Earlier this week, The New York Times reported validation that a PET agent developed by a small start-up company in Pennsylvania could light up plaques in the brains of patients with memory problems, allowing a definitive diagnosis of Alzheimer’s disease. With such an agent, the NYT reported, it would be possible to determine whether drugs now being developed are slowing or halting the disease process. The results are expected to be presented at an international meeting of the Alzheimer’s Association in Honolulu on July 11. They are especially noteworthy in that they correlate pathological data obtained at autopsy with scan data obtained when the patients were alive.

See full article and related articles at DiagnosticImaging.com
This article was republished with permission from CMPMedica, LLC

Views: 9

Tags: alzheimer, dementia, diagnosticimaging, pet

Comment

You need to be a member of radRounds Radiology Network to add comments!

Join radRounds Radiology Network

Promotions and Sponsorships on radRounds

Search latest Imaging news and info:

Powered by Diagnostic Imaging

Invite five colleagues who ultimately register and receive a $10 Starbucks Gift Card! (US Members Only due to Federal Regulations)

© 2014   Created by radRounds Radiology Network.

Badges  |  Report an Issue  |  Terms of Service